Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase

Pauwels, 1990, Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature, 343, 470, 10.1038/343470a0 Merluzzi, 1990, Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor, Science, 250, 1411, 10.1126/science.1701568 Saari, 1991, 2-pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors, J Med Chem, 34, 2922, 10.1021/jm00113a036 Balzarini, 1992, [2′,5′-Bis-O-(tert-butyldimethylsilyl)]- 3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1, Antimicrob Agents Chemother, 36, 1073, 10.1128/AAC.36.5.1073 Romero, 1991, Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication, Proc Natl Acad Sci USA, 88, 8806, 10.1073/pnas.88.19.8806 Montaner, 1998, A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial, Italy, The Netherlands, Canada and Australia Study. JAMA, 279, 12, 930, 937 Ruiz, N. A double-blind pilot study to evaluate the antiretroviral activity, tolerability of DMP 266 in combination with indinavir (cohort III) Staszewski, S. Morales-Ramirez, J. Flanigan, T. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) +lamivudine (3TC) versus IDV + ZDV + 3TC at 24 weeks [Abstract 22336], 1998 Green, S. Para, M. F. Daly, P. W. Interim analysis of plasma viral burden reductions and CD4+ increases in HIV-1 infected patients with Rescriptor (DLV)+Retrovir (ZDV)+Epivir (3TC) [Abstract 12219], 1998 Wu, 1991, A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site, Biochemistry, 30, 2022, 10.1021/bi00222a003 Cohen, 1991, Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase, J Biol Chem, 266, 14670, 10.1016/S0021-9258(18)98737-5 Ding, 1995, Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8A resolution, Structure, 3, 365, 10.1016/S0969-2126(01)00168-X Smerdon, 1994, Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1, Proc.Nat.Acad.Sci.USA, 91, 3911, 10.1073/pnas.91.9.3911 Sayle, 1995, RASMOL: biomolecular graphics for all, Trends in Biochem Sci, 20, 374, 10.1016/S0968-0004(00)89080-5 Boyer, 1994, Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents and Chemother., 38, 1909, 10.1128/AAC.38.9.1909 Jonckheere, 1994, Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′, 2′′-dioxide)] (TSAO) derivatives is determined by the mutation Glu 138->Lys on the p51 subunit, J Biol Chem, 269, 25255, 10.1016/S0021-9258(18)47240-7 Esnouf, 1997, Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor, Proc Natl Acad Sci USA, 94, 3984, 10.1073/pnas.94.8.3984 Hsiou, 1996, Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms, Structure, 4, 853, 10.1016/S0969-2126(96)00091-3 Hsiou, Y. Das, K. Ding, J. Crystal structures of wild-type and mutant HIV-1 reverse transcriptase and non nucleoside inhibitors: implications for drug resistance mechanisms Das, 1996, Crystal structures of 8-Cl and 9-C1 TIBO complexed with wild-type HIV-1 RT and 8-C1 TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant, J Mol Biol, 264, 1085, 10.1006/jmbi.1996.0698 Boyer, 1998, A mutation at position 190 of human innumodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer, Antimicorb. Agents and Chemother., 42, 447, 10.1128/AAC.42.2.447 Pelemans, 1997, A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152, J Gen Virol, 79, 1347, 10.1099/0022-1317-79-6-1347 Maga, 1997, Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions, J. Mol. Biol., 274, 738, 10.1006/jmbi.1997.1427 Bacolla, 1993, Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2, Effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem, 268, 16577 Quinones-Mateu, 1997, Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate, Virology, 236, 364, 10.1006/viro.1997.8748 Descamps, 1995, HIV-1 group O sensitivity to antiretroviral drugs, AIDS, 9, 977, 10.1097/00002030-199508000-00026 Descamps, 1997, Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses, J Virol, 71, 8893, 10.1128/JVI.71.11.8893-8898.1997 1991, Proc Natl Acad. SCA U S A, 88, 9878, 10.1073/pnas.88.21.9878 Condra, 1992, Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors, Antimicrob. Agents and Chemother, 36, 1441, 10.1128/AAC.36.7.1441 Isaka, 1997, Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor, Microbiol Immunol, 42, 3, 195, 202 Deschamps, D. Apetrei, C. Collin, G. Damond, F. Simon, F. Brun-Vezinet, F. In vitro drug susceptibility and sequence analysis of HIV-1 group M isolates belonging to different subtypes Richman, 1991, Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture, Proc Natl Acad Sci U S A, 88, 11241, 10.1073/pnas.88.24.11241 Mellors, 1992, In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase, Mol Pharmacol, 41, 446 Wei, 1995, Viral dynamics in human immunodeficienty virus type 1 infection, Nature, 373, 117, 10.1038/373117a0 1995, Nature, 373, 123, 10.1038/373123a0 Perelson, 1996, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science, 271, 1582, 10.1126/science.271.5255.1582 Mansky, 1995, Lower in vivo mutation rate of human immunodeficiency virus type 1 than thatpredicted from the fidelity of purified reverse transcriptase, J Virol, 69, 5087, 10.1128/JVI.69.8.5087-5094.1995 Coffin, 1995, HIV Populations dynamics in vivo: impliciations for genetic variation, pathogenesis, and therapy, Science, 267, 483, 10.1126/science.7824947 Larder, 1996, Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′, 3′- dideoxyinosine or AZT plus 2′, 3′-dideoxycytidine combination therapy, The protocol 34,225-02 Collaborative Group. J Virol, 70, 5922 Havlir, 1996, Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients, J Virol, 70, 7894, 10.1128/JVI.70.11.7894-7899.1996 Kleim, 1997, In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097, Virology, 231, 112, 10.1006/viro.1997.8513 1997, Antiviral Research, 33, 109, 10.1016/S0166-3542(96)01008-X Keulen, 1996, Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins, Antiviral Research, 31, 45, 10.1016/0166-3542(96)00944-8 Richman, 1994, Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy, J Virol, 68, 1660, 10.1128/JVI.68.3.1660-1666.1994 Richman, 1995, A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/Mm3: AIDS Clinical Trials Group Protocol 208, J Infect Dis, 172, 1379, 10.1093/infdis/172.5.1379 Cheeseman, 1995, Phase I/II evalutation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus, J AIDS and Hum Retrovirol, 8, 141 Havlir, 1995, High-dose nevirpaine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection, J of Infect D, 171, 537, 10.1093/infdis/171.3.537 Carr, 1996, A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-1 infected patients, The Dutch-Italian, Australian Nevirapine Study Group., AIDS, 10, 635 Dueweke, 1993, A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors, Proc Natl Acad Sci U S A, 90, 4713, 10.1073/pnas.90.10.4713 Fan, 1995, Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s, FEBS Lett, 370, 59, 10.1016/0014-5793(95)00793-9 Wathen, L. K. Freimuth, W. W. Batts, D. H. Cox, S. R. Phenotypic and genotypic characterization of HIV-1 isolates from patients treated with combined AZT and delavirdine mesylate (DLV) therapy, 3rd International Workshop on HIV Drug Resistance, Kauai, HI, 1995:42. Freimuth, 1996, Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor, Adv Exp Med Biol, 394, 279, 10.1007/978-1-4757-9209-6_25 Demeter, 1996 Salzman, NK, Lanne, H. C. Chappey, C. Patterns of HIV drug resistance during combined or monotherapy with delavirdine Been-Taktak, 1995, Combination therapy with delavirdine mesylate (DLV) and AZT: virology data from an European Phase II trial, J Acquir Immune Defic Syndr Hum Retroviruses, 10, s23 Demeter, 1997, HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine, J Acquir Immune Defic Syndr Hum Retrovirol, 14, 136, 10.1097/00042560-199702010-00006 Winslow, 1996, Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266, AIDS, 10, 1205, 10.1097/00002030-199609000-00005 Bacheler, 1997 Bacheler, L. George, H. Hollis, G. Resistance to efavirenz (Sustiva) in vivo. 5th Conference on Retroviruses and Opportunistic Infections, 1998 Bacheler, L. T. Anton, E. Jeffrey, S. RT gene mutations associated with resistance to efavirenz Katzenstein, D. A. Shafer, R. W. Bosch, R. J. Albrecht, M. Hammer, S. M. Reverse transcriptase and protease genotypes of nucleoside-experienced subjects with virological failure on nelfinavir or efavirnez Seki, 1995, Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442, Antiviral Chem. and Chemother., 6, 73, 10.1177/095632029500600201 Harris, 1998, Development of genotypic and phenotypic resistance to MKC-442, a potent and selective inhibitor of HIV-1 replication, Antiviral Res, 37 Schmit, 1996, Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain, J Infect Dis, 174, 962, 10.1093/infdis/174.5.962 Staszewski, 1996, Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients, AIDS, 10, F1, 10.1097/00002030-199605000-00001 Jeffrey, S. Baker, D. Tritch, R. Rizzo, C. Bacheler, L. A resistance and cross resistance profile for Sustiva® (efavirenz, DMP 266), 1998 Moeremans, M. Raeymaeker, M. Van den Broeck, R. Stoffels, P. Andries, K. Genotypic analysis of HIV-1 isolates from patients receiving loviride alone, or in combination with mucleoside reverse transcrptase inhibitos Miller, 1997, Clinical experience with non-nucleoside reverse transcriptase inhibitors, AIDS, 11(supplA), S157 Nunberg, 1991, Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors, J Virol, 65, 4887, 10.1128/JVI.65.9.4887-4892.1991 Saag, 1993, A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, L-697,661 Working Group. N Engl J Med, 329, 1065, 10.1056/NEJM199310073291502 Schooley, 1996, Phase 1 study of combination therapy with L-697,661 and zidovudine, The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol, 12, 363, 10.1097/00042560-199608010-00006 Staszewski, 1995, Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor, J Infect Dis, 171, 1159, 10.1093/infdis/171.5.1159 Balzarini, 1996, Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication, Mol Pharmacol, 50, 394 Buckheit, 1997, Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1, AIDS Res Hum Retroviruses, 13, 789, 10.1089/aid.1997.13.789 Balzarini, 1998, A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781, AIDS Res Hum Retroviruses, 14, 255, 10.1089/aid.1998.14.255 Olmsted, R. A. Slade, D. E. Kopta, L. A. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes, J Virol, 1996, 70, 3698, 3705 Balzarini, 1993, Proc Natl Acad Sci USA, 90, 6952, 10.1073/pnas.90.15.6952 Fujiwara, 1998, S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1, Antimicrob. Agents Chemother., 42, 1340, 10.1128/AAC.42.6.1340 Young, 1995, L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob Agents Chemother, 39, 2602, 10.1128/AAC.39.12.2602 Pelemans, 1997, Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1, J Virol, 71, 8195, 10.1128/JVI.71.11.8195-8203.1997 Kleim, 1997, In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097, Virology, 231, 112, 10.1006/viro.1997.8513 1992, Antimicrob Agents Chemother, 36, 2664, 10.1128/AAC.36.12.2664 Byrnes, 1994, Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to revese transcriptase inhibitors, Antimicrob Agents Chemother., 38, 1404, 10.1128/AAC.38.6.1404 Tisdale, 1993, Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase, Proc Natl Acad Sci USA, 90, 5653, 10.1073/pnas.90.12.5653 Boucher, 1993, High-level resistance to (–) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase, Antimicrob Agents Chemother, 37, 2231, 10.1128/AAC.37.10.2231 Larder, 1995, Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy, Science, 269, 699, 10.1126/science.7542804 Rezende, 1998, The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase, Nucleic Acids Res, 26, 3072, 10.1093/nar/26.12.3066 Hsu, 1997, Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1, Nucleic Acids Res, 25, 4532, 10.1093/nar/25.22.4532 Hamburgh, 1998, The influence of 3TC-resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency, Nucl. Acids Res., 26, 4389, 10.1093/nar/26.19.4389 Wainberg, 1996, Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase, Science, 271, 1282, 10.1126/science.271.5253.1282 Wainberg, 1997, Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials, Leukemia, 11, 85 Drosopoulos, 1998, Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro, J Virol, 72, 4224, 10.1128/JVI.72.5.4224-4230.1998 Jonckheere, 1998, Lamivudine resistance of hiv type 1 does not delay development of resistance to nonnucleoside hiv type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1, AIDS Res Hum Retroviruses, 14, 249, 10.1089/aid.1998.14.249 Balzarini J and Kleim, 1997, Drug resistance development of HIV-1 upon combination therapy with 3TC And NNRTIS, International Antiviral News, 5, 6 Schuurman, 1995, Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC), J Infect Dis, 171, 1411, 10.1093/infdis/171.6.1411 Balzarini, 1996, Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors, Proc Natl Acad Sci USA, 93, 13152, 10.1073/pnas.93.23.13152 Kleim, 1995, Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication, Antimicrob Agents Chemother, 39, 2253, 10.1128/AAC.39.10.2253 Kleim, 1996, Proc. Natl. Acad. Sci. USA, 93, 34, 10.1073/pnas.93.1.34 Havlir, 1995, High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection, J Infect Dis, 171, 537, 10.1093/infdis/171.3.537 de Jong, 1997, High-dose nevirapine in previously untreated human immunodificienty virus type 1-infected persons does not result in sustained suppression of viral replication, J of Infect Diseases, 175, 966, 10.1086/514002